Target intelligence / Profile preview

Antigen Presentation System

Molecular classification
Other (not a receptor, enzyme, transporter, or simple protein family), Pathway/process, Includes molecules of the major histocompatibility complex (MHC class I and II)
01

Overview

The antigen presentation system refers to the immune process in which antigens, typically derived from pathogens or abnormal host cells, are processed and displayed on the cell surface by major histocompatibility complex (MHC) molecules. This display enables T lymphocytes, crucial players of adaptive immunity, to recognize and mount a targeted immune response. Professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells are central to this process, as they process exogenous antigens (via MHC class II) or endogenous antigens (via MHC class I), and provide the necessary costimulatory signals for T cell activation. The efficiency and regulation of this system are critical for defense against pathogens and tumor cells, and for maintaining self-tolerance to avoid autoimmune reactions.

Other names
Antigen presentationAntigen processing and presentationAntigen-presenting pathway
02

Mechanism of action

Many immunotherapies work by enhancing or inhibiting antigen presentation, e.g., monoclonal antibodies targeting checkpoint molecules (PD-1, CTLA-4) to promote T cell activation. Adjuvants in vaccines often enhance antigen presentation by stimulating APC maturation.

03

Biological functions

Immune responseSignal induction and regulation (bridging innate and adaptive immunity)T cell activation
04

Disease associations

Infection (essential for detecting and responding to pathogens)Cancer (presentation of tumor antigens)Autoimmune disease (errors in self-antigen presentation may cause inappropriate T cell responses)
05

Safety considerations

Excessive or inappropriate stimulation can lead to autoimmunityInsufficient antigen presentation can impair immune defense against infections or cancer
06

Interacting drugs

No direct drugs interact with an "antigen presentation system" entity, but many immunotherapies (such as immune checkpoint inhibitors) indirectly affect these processes
07

Biomarkers

Expression of MHC molecules (HLA typing)Presence/activation status of dendritic cells, B cells, macrophagesPeptide-MHC complexes detected by specific reagents

Beyond the preview

Go deeper on Antigen Presentation System.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antigen Presentation System.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call